HOME > COMMENTARY
COMMENTARY
-
Top Wholesalers Cut Costs to Offset Declines in Gross Profits
December 5, 2005
-
Importance of Framing
November 21, 2005
-
A Cluster of Diseases - Metabolic Syndrome: Reflecting Aging Society
November 7, 2005
-
A Cluster of Diseases - Metabolic Syndrome:Reflecting an Aging Society -1-
October 31, 2005
-
Commentary 2005 Will Be "Year 1" of Japanese Drug Industry Reorganization
October 17, 2005
-
COMMENTARY 2 articles
October 10, 2005
-
COMMENTARY 6 articles
September 19, 2005
-
Where Will the Japanese Pharmaceutical Industry Drift? - From "The Sky Is the Limit" to the Abyss -
August 29, 2005
-
COMMENTARY 5 articles
August 8, 2005
-
2 Rosai Hospitals Start Prescriptions by the Generic Name
July 25, 2005
-
COMMENTARY 6 articles
July 25, 2005
-
Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (3)
July 4, 2005
-
Former Reviewers' Interviews Make OPIR Report Exciting
June 27, 2005
-
Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)
June 27, 2005
-
Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (1)
June 20, 2005
-
Special Contribution
May 16, 2005
-
Japan's Most Admired Pharma Companies P. Reed Maurer President, NPP
April 18, 2005
-
PRTM Shows Results of Investigational Drug Survey
March 14, 2005
-
<Special Comtribution>
March 7, 2005
-
<Special Comtribution>
March 7, 2005
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
